Additional file 1 of Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial

Additional file 1: Tables S1. Between-group comparison of changes in clinical parameters during the treatment period. Table S2. Changes in concomitantly used anti-diabetic agents. Table S3. Changes in concomitantly used cardiovascular medications. Table S4. The changes of GSM-CCA on the basis of tertiles of changes in mean-IMT during observation perio

Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol

<p><b>Article full text</b><br></p> <p><br></p> <p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0351-7"><b>here</b>.</a></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p> </p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p> <p> </p> <p> </p

Additional file 2 of Improvement of beta-cell function in conjunction with glycemic control after medical nutrition therapy in newly-diagnosed type 2 diabetes mellitus

Additional file 2: Appendix S1. Medical nutrition therapy at Shiraiwa Medical Clinic

Additional file 1 of Improvement of beta-cell function in conjunction with glycemic control after medical nutrition therapy in newly-diagnosed type 2 diabetes mellitus

Additional file 1: Table S1. Patients who were newly diagnosed with type 2 diabetes and started their treatment at the study clinic during the study period. Table S2. Change of other insulin secretion/sensitivity-related indices after MNT. Table S3. Correlation of HbA1c and BMI with other insulin secretion/sensitivity-related indices (n = 68). Figure S1. Correlation of HbA1c and BMI with insulin sensitivity index (ΔI0–120/ΔG0–120), HOMA-β, and HOMA-IR (n = 68). Table S4. Correlation of HbA1c and BMI with disposition index and Matsuda’s insulin sensitivity index by baseline HbA1c (n = 68). Table S5. Correlation of HbA1c and BMI with other insulin secretion/sensitivity-related indices by baseline HbA1c (n = 68). Table S6. Association of clinical characteristics with disposition index, Matsuda’s insulin sensitivity index, and other indices (n = 68)

The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis

<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0267-2"><b>here</b>.</a><br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides<u></u></p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p

Multiple linear regression analyses between %body fat and logarithmic serum ucOC or OC concentration.

Multiple linear regression analyses between %body fat and logarithmic serum ucOC or OC concentration.</p

UcOC and OC were inversely correlated with %body fat.

The correlation between %body fat and ucOC (A), OC (B), log ucOC (C) and log OC (D). Pearson’s correlation coefficients (r), P values and regression equations are shown.</p

Correlations between logarithmic serum ucOC and OC concentrations and each parameter in univariate models.

Correlations between logarithmic serum ucOC and OC concentrations and each parameter in univariate models.</p

Clinical characteristics of the participants.

Clinical characteristics of the participants.</p

Two-way ANOVA for %body fat concerning factors of gender and categorical variables of ucOC or OC.

There were significant differences in %body fat by gender (P = 0.0086, in the ucOC model; P = 0.0097, in the OC model). In contrast, there were no significant differences in %body fat by categorical variables of ucOC or OC (P = 0.185; P = 0.094, respectively). In addition, there were no significant interactions between gender and ucOC or OC (P = 0.356; P = 0.671, respectively). * Statistically significant (P < 0.05).</p